We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
Read MoreHide Full Article
Shares of Horizon Therapeutics Public Limited Company have surged 90.3% year to date compared with the industry’s growth of 0.1%.The year has been good for the company with several positive regulatory and pipeline developments.Some factors that have led to the growth are as follows.
In January 2020, the FDA approved the company’sdrug, Tepezza, for the treatment ofpatients with thyroid eye disease (TED). With the approval, Tepezza became the first FDA-approved medicine for the treatment of active TED, which has a significant unmet need. The launch of the drug has been encouraging despite a challenging COVID-19 environment. Based on the continued strength of Tepezza, the company increased both the drug and 2020’s net sales guidanceduring the third-quarter conference call held in November.
Further, Horizon is working on the label expansion of marketed drugs like Tepezza, Krystexxa, Actimmune, Procysbi and Ravicti. The company expects to initiate a study on Tepezza in patients with chronic TED.
The label expansions will further boost sales of the company.
In February, the FDA approved Procysbi delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another administration option for patients, in addition to the currently available Procysbi capsules.
On Apr 1, the company completed the acquisition of Curzion Pharmaceuticals, Inc. and its lysophosphatidic acid 1 receptor (LPAR1) antagonist candidate (renamed HZN-825) for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). The company expects to begin a pivotal phase IIb study on the same in the first half of 2021.The company’s growth-by-acquisition strategy is encouraging.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Shares of the company have decreased 7.9% year to date.
Abeona’s loss per share estimates have narrowed from 96 cents to 88 cents for 2020 and from 69 cents to 64 cents for 2021 over the past 60 days. Shares of the company have decreased 56.9% year to date.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days. Shares of the company have decreased 37.4% year to date.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
Shares of Horizon Therapeutics Public Limited Company have surged 90.3% year to date compared with the industry’s growth of 0.1%.The year has been good for the company with several positive regulatory and pipeline developments.Some factors that have led to the growth are as follows.
In January 2020, the FDA approved the company’sdrug, Tepezza, for the treatment ofpatients with thyroid eye disease (TED). With the approval, Tepezza became the first FDA-approved medicine for the treatment of active TED, which has a significant unmet need. The launch of the drug has been encouraging despite a challenging COVID-19 environment. Based on the continued strength of Tepezza, the company increased both the drug and 2020’s net sales guidanceduring the third-quarter conference call held in November.
Further, Horizon is working on the label expansion of marketed drugs like Tepezza, Krystexxa, Actimmune, Procysbi and Ravicti. The company expects to initiate a study on Tepezza in patients with chronic TED.
The label expansions will further boost sales of the company.
In February, the FDA approved Procysbi delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another administration option for patients, in addition to the currently available Procysbi capsules.
On Apr 1, the company completed the acquisition of Curzion Pharmaceuticals, Inc. and its lysophosphatidic acid 1 receptor (LPAR1) antagonist candidate (renamed HZN-825) for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). The company expects to begin a pivotal phase IIb study on the same in the first half of 2021.The company’s growth-by-acquisition strategy is encouraging.
Zacks Rank & Stocks to Consider
Horizon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include ASLAN Pharmaceuticals Ltd. (ASLN - Free Report) , Abeona Therapeutics Inc. and Alimera Sciences Inc. (ALIM - Free Report) . All of them carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Shares of the company have decreased 7.9% year to date.
Abeona’s loss per share estimates have narrowed from 96 cents to 88 cents for 2020 and from 69 cents to 64 cents for 2021 over the past 60 days. Shares of the company have decreased 56.9% year to date.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days. Shares of the company have decreased 37.4% year to date.
Horizon Therapeutics Public Limited Company Price
Horizon Therapeutics Public Limited Company price | Horizon Therapeutics Public Limited Company Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>